Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valenca Bueno L, Andrade LMQS, Patrikidou A, Mestre RP, Modesti M, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E; SPARTACUSS Investigators. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023 Feb 3;21(1):75. PMID: 36737752; PMCID: PMC9896712.

Gennusa V, Saieva C, Lee-Ying RM, Nuzzo PV, Spinelli GP, Zanardi E, Fotia G, Rossetti S, Valenca LB, Patrikidou A, Andrade L, Mestre RP, Fornarini G, Procopio G, Santini D, Sweeney C, Chin Heng DY, Giorgi U, Russo A, Francini E. Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study. Journal of Clinical Oncology (ASCO Genitourinary Cancers Symposium) 2023 41:6_suppl, 166-166

Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators (Andrade, L). Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. Epub 2023 Mar 23. PMID: 36952634; PMCID: PMC10431499.

Shore ND, Fizazi K, Tammela T, Luz M, Salas MP, Ouellette P, Lago S, Bastos DA, Jansz GK, Carcano FM, Andrade L, Pliskin M, Lazaretti N, Arruda L, Correa JJ, Petrenciuc O, Kappeler C, Sarapohja T, Smith MR. Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial. Journal of Clinical Oncology (Genitourinary Cancers Symposium) 2021 39:6_suppl, 240-240

Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O’Shaughnessy J; IMpassion131 investigators. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021 Aug;32(8):994-1004. Epub 2021 Jul 1. PMID: 34219000.